Finding accredited CPD
Originally introduced for type 2 diabetes mellitus, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained significant market traction for the treatment of patients with obesity. There is global heterogeneity across health systems in how these agents are currently used and supplied, which patient cohorts are eligible, how and for whom they are funded and for what duration.
This MJA Perspective shares more.
Authors: Christopher Kanellis, Kyle Williams, Darcy Q Holt, Jennifer Wong, Rachel David, Ravi Carothers and Suong Le
Article Type: Perspective
Provided by
Educational Activities (EA) - 0.30
Reviewing Performance (RP) - 0.0
Measuring Outcomes (MO) - 0.0
You have to log in to see the content of this module.
*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)
